KRT5 and prostate neoplasm: As shown in Figure 4b, nearly 44% (23/52, sample ID labeled in red) of the prostate tumors showed the 'dasatinib-responsive' expression patterns (that is, low AR and PSA and high uPA, EphA2 and/or CK5).